SFL’s Senior Market Access Manager to attend discussion on AMNOG and the evaluation of new pharmaceuticals in Germany
SFL’s Senior Manager Market Access and HEOR, Daniel Dröschel>, will attend abackground discussion panel on “AMNOG 2.0″/a> wiProf. James Robinson/a> from UC Berkeley (23 May 2019, Berlin). Daniel was one of over 30 experts interviewed by Prof. Robinson to provide their insights on the mechanisms of the German Market and the current Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) that controls the entry of new pharmaceutics onto the German market. The discussion panel, organized by the BMC association (Bundesverband Managed Care), will examine potential future developments in pricing and the increasing challenges in the application of AMNOG to medicines with a relatively small clinical data base, such as orphan drugs and biosimilars, as well as the use of reference price groups.
Daniel and SFL’s reimbursement team have many years of experience in the field and are experts in applying relevant Regulations across the EU to develop sustainable value strategies for pharmaceuticals and medical devices. He would be happy to meet at the event and discuss how changes in the Market Access field could affect your projects, or pleacontact us/a> to arrange a call with Daniel.